VX1 Stock Overview
A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VX1 from our risk checks.
Vertex Pharmaceuticals Incorporated Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$457.30 |
52 Week High | US$475.90 |
52 Week Low | US$315.10 |
Beta | 0.40 |
11 Month Change | 11.62% |
3 Month Change | 7.60% |
1 Year Change | 28.44% |
33 Year Change | 176.21% |
5 Year Change | 143.87% |
Change since IPO | 1,536.14% |
Recent News & Updates
Recent updates
Shareholder Returns
VX1 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 5.3% | 0.7% | -1.3% |
1Y | 28.4% | -15.4% | 13.9% |
Return vs Industry: VX1 exceeded the German Biotechs industry which returned -15.4% over the past year.
Return vs Market: VX1 exceeded the German Market which returned 13.9% over the past year.
Price Volatility
VX1 volatility | |
---|---|
VX1 Average Weekly Movement | 3.5% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 11.5% |
10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: VX1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: VX1's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 5,400 | Reshma Kewalramani | www.vrtx.com |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.
Vertex Pharmaceuticals Incorporated Fundamentals Summary
VX1 fundamental statistics | |
---|---|
Market cap | €119.93b |
Earnings (TTM) | -€446.98m |
Revenue (TTM) | €9.90b |
12.0x
P/S Ratio-265.0x
P/E RatioIs VX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VX1 income statement (TTM) | |
---|---|
Revenue | US$10.63b |
Cost of Revenue | US$4.77b |
Gross Profit | US$5.86b |
Other Expenses | US$6.34b |
Earnings | -US$479.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.86 |
Gross Margin | 55.13% |
Net Profit Margin | -4.52% |
Debt/Equity Ratio | 0% |
How did VX1 perform over the long term?
See historical performance and comparison